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ABSTRACT
Objectives To determine the contribution of 
comorbidities on the reported widespread myocardial 
abnormalities in patients with recent COVID- 19.
Methods In a prospective two- centre observational 
study, patients hospitalised with confirmed COVID- 19 
underwent gadolinium and manganese- enhanced 
MRI and CT coronary angiography (CTCA). They were 
compared with healthy and comorbidity- matched 
volunteers after blinded analysis.
Results In 52 patients (median age: 54 (IQR 51–57) 
years, 39 males) who recovered from COVID- 19, 
one- third (n=15, 29%) were admitted to intensive 
care and a fifth (n=11, 21%) were ventilated. 
Twenty- three patients underwent CTCA, with one- 
third having underlying coronary artery disease (n=8, 
35%). Compared with younger healthy volunteers 
(n=10), patients demonstrated reduced left (ejection 
fraction (EF): 57.4±11.1 (95% CI 54.0 to 60.1) versus 
66.3±5 (95 CI 62.4 to 69.8)%; p=0.02) and right (EF: 
51.7±9.1 (95% CI 53.9 to 60.1) vs 60.5±4.9 (95% 
CI 57.1 to 63.2)%; p≤0.0001) ventricular systolic 
function with elevated native T1 values (1225±46 
(95% CI 1205 to 1240) vs 1197±30 (95% CI 1178 to 
1216) ms;p=0.04) and extracellular volume fraction 
(ECV) (31±4 (95% CI 29.6 to 32.1) vs 24±3 (95% CI 
22.4 to 26.4)%; p<0.0003) but reduced myocardial 
manganese uptake (6.9±0.9 (95% CI 6.5 to 7.3) vs 
7.9±1.2 (95% CI 7.4 to 8.5) mL/100 g/min; p=0.01). 
Compared with comorbidity- matched volunteers 
(n=26), patients had preserved left ventricular function 
but reduced right ventricular systolic function (EF: 
51.7±9.1 (95% CI 53.9 to 60.1) vs 59.3±4.9 (95% CI 
51.0 to 66.5)%; p=0.0005) with comparable native T1 
values (1225±46 (95% CI 1205 to 1240) vs 1227±51 
(95% CI 1208 to 1246) ms; p=0.99), ECV (31±4 (95% 
CI 29.6 to 32.1) vs 29±5 (95% CI 27.0 to 31.2)%; 
p=0.35), presence of late gadolinium enhancement 
and manganese uptake. These findings remained 
irrespective of COVID- 19 disease severity, presence of 
myocardial injury or ongoing symptoms.
Conclusions Patients demonstrate right but not 
left ventricular dysfunction. Previous reports of 
left ventricular myocardial abnormalities following 
COVID- 19 may reflect pre- existing comorbidities.
Trial registration number NCT04625075.
INTRODUCTION
In patients with COVID- 19, there remains major 
concern surrounding the extent of cardiac involve-
ment and its consequences. Myocardial injury is 
common in patients hospitalised with COVID- 19 
and correlates with disease severity and poor clinical 
outcomes.1–3 The mechanisms underlying this are 
not well understood, with some suggesting indirect 
mechanisms of injury similar to that of other severe 
respiratory illnesses.2 4–9 Others have proposed direct 
myocardial injury due to myocarditis, stress cardio-
myopathy, endothelial injury, thromboinflammation 
or the result of profound ongoing myocardial oxygen 
supply or demand imbalance.5 10–14
There are increasing reports of persistent 
and prolonged multiorgan effects after acute 
COVID- 19 illness.15 16 More importantly, many 
patients continue to have debilitating symptoms 
during recovery,16 and it is important to understand 
whether cardiac damage observed in the acute 
phase of COVID- 19 will translate into subsequent 
cardiac dysfunction and morbidity. Widespread 
myocardial abnormalities seen on cardiac MRI have 
been reported in patients with COVID- 19.8 10–12 
However, a large proportion of these patients have 
comorbidities, and the presence of coronary artery 
disease had not been excluded. It is therefore essen-
tial to understand whether such cardiac abnormali-
ties are the result of underlying comorbidities or the 
direct impact of COVID- 19.
Manganese- enhanced MRI has shown promise in 
assessing myocardial calcium handling17 and may 
measure more subtle disturbances in myocardial 
function. Using both gadolinium and manganese- 
enhanced MRI combined with CT coronary angi-
ography, we sought to determine the contribution 
and impact of pre- existing cardiovascular disease 
on the cardiac abnormalities of patients recovering 
from COVID- 19 hospitalisation.
METHODS
Written informed consent was obtained from all 
participants.
Participants
Adult patients recovering from hospitalisation with 
COVID- 19 were recruited prospectively from the 
Edinburgh Heart Centre between May 2020 and 
November 2020 and Glenfield Hospital, Leicester 
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between November 2020 and February 2021. The diagnosis 
of COVID- 19 was based on a positive PCR test. Comparisons 
were made with healthy volunteers (10 participants) and volun-
teers matched for age, sex and comorbidities (26 participants). 
Patients and comorbid volunteers were propensity matched 1:2 
to cardiovascular risk factors including hypertension, known 
ischaemic heart disease, hypercholestrolaemia and diabetes 
mellitus. Matched volunteers were recruited from general cardi-
ology admissions, outpatient clinic or those recruited for other 
cardiac studies. The latter control group were scanned at Glen-
field Hospital prior to January 2020 (n=16) or at the Univer-
sity of Edinburgh (n=10) between September 2020 and January 
2021. Matched (n=6) and healthy volunteers (n=10) scanned 
during the pandemic were eligible once previous COVID- 19 
infection or current symptoms of COVID- 19 were excluded. 
The majority of this cohort (matched n=6, healthy n=8) under-
went regular PCR testing during hospital admission or due to 
occupational requirements. Exclusion criteria for all participants 
included contraindications to MRI or manganese dipyridoxyl 
diphosphate administration (online supplemental methods).
Myocardial injury was defined as plasma cardiac troponin I 
concentration above the 99th centile (female: 16 ng/L, male: 
34 ng/L) but was not necessary for inclusion. Quick COVID- 19 
severity index was used to assess severity with severe cases 
defined as having an index of  >4 (>30% risk of critical illness) 
(online supplemental methods).18
Magnetic resonance imaging
MRI in Edinburgh was performed using a Siemens MAGNETOM 
Skyrafit 3T scanner (Siemens Healthineers, Erlangen, Germany) 
with a dedicated 30- channel body matrix coil. MRI in Leicester 
was performed using a Siemens MAGNETOM Skyra 3T scanner 
(Siemens Healthineers, Erlangen, Germany) with an 18- channel 
cardiac coil. All study participants underwent imaging with 
late gadolinium enhancement. Patients from Edinburgh and all 
healthy volunteers underwent additional manganese- enhanced 
MRI, at least 48 hours apart. Patients were scanned during 
convalescence. Images were acquired during expiratory breath 
hold with ECG gating. Cine imaging was acquired with standard 
steady- state free precession sequences in long- axis and short- axis 
orientations as described previously.17 T2 mapping (MyoMaps) 
was acquired in the short- axis orientation covering the entire 
left ventricle. Native T1 mapping was acquired with a Modified 
Look- Locker Inversion recovery short- axis stack. Patients with 
COVID- 19 scanned in Leicester underwent native T1 mapping 
with a shortened modified Look- Locker inversion recovery 
short- axis stack.
Late gadolinium enhancement
Late gadolinium enhancement images were acquired following 
intravenous gadobutrol (0.1 mmol/kg; Gadovist, Bayer, 
Germany)19 using a single breath hold per slice with a short- axis 
stack and long- axis orientations. T1 mapping was acquired prior 
to and 10 min postcontrast (online supplemental methods).
Manganese-enhanced MRI
Manganese- enhanced MRI was carried out using intravenous 
infusion of manganese dipyridoxyl diphosphate (5 µmol/kg, 1 
mL/min, 0.1 mL/kg; Exova SL Pharma, Wilmington, Delaware, 
USA). T1 mapping was performed precontrast with a full short- 
axis Modified Look- Locker Inversion recovery stack, which have 
been described previously (online supplemental methods).17
Image analysis
Cardiovascular magnetic resonance studies were analysed offline 
using Circle CVI (Circle Cardiovascular Imaging, CVI42 V.5.3.6, 
Calgary Canada). T1, T2 maps, late gadolinium enhancement 
and cine- derived volumetric and functional sequences were anal-
ysed by experienced observers (MD, TS and TAK). Native T1and 
T2 measurements were taken from septal segments, although 
we also report results for global T1. T1 mapping acquired 
using shortened modified Look- Locker inversion recovery was 
excluded from native T1 analysis but not from extracellular 
volume analysis. Areas of late gadolinium enhancement were 
included for calculating global extra cellular volume. Late gado-
linium enhancement was adjudicated by consensus of expert 
observers (GPM and JRA) who were blinded to all participant 
details (including whether scans were from patients or volun-
teers) and classified as ischaemic or non- ischaemic (midwall or 
epicardial) pattern. Right ventricular insertion point enhance-
ment in isolation was not considered pathological.
Manganese kinetic modelling
Myocardial calcium handling was assessed using T1 maps during 
manganese- enhanced MRI.20 21 Regions of interest were drawn 
in areas of myocardial abnormalities or the midventricular 
septum in those without myocardial abnormalities (mean size: 
0.7±0.13 cm2). The rate of myocardial manganese uptake was 
determined by Patlak modelling as described previously.17
CT coronary angiography (CTCA)
Patients scanned in Edinburgh underwent CTCA, which was 
performed with a 128- multidetector row scanner (Siemens 
Biograph, Siemens Healthcare, Erlangen, Germany) according 
Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of 
Reporting Trials; CTCA, CT coronary angiography; ECMO, extracorporeal 
membrane oxygenation; PIL, patient information leaflet.
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to Society of Cardiovascular Computed Tomography guide-
lines and have been described previously (online supplemental 
methods).22
Statistical analysis
All statistical analyses were performed with GraphPad Prism 
(GraphPad Software V.8.0.2, San Diego, California, USA). 
Categorical baseline variables were presented as number (%) 
and compared using χ2 test. Continuous data were assessed 
for normality using the D’Agostino- Pearson test and presented 
as mean±SD or median (IQR). Cardiac function, myocar-
dial manganese uptake, volumetric assessment and parametric 
mapping values were compared using paired or unpaired 
Student’s t- tests, Wilcoxon or Mann- Whitney tests and 
ANOVA±Dunnett’s as appropriate. Statistical significance was 
taken as two- sided p<0.05.
RESULTS
Study populations
Fifty- four patients recovering from COVID- 19 were recruited 
into the study with two patients withdrawing due to problems 
with vascular access or claustrophobia (figure 1). Ten healthy 
volunteers and 26 volunteer patients matched for age, sex and 
comorbidities were recruited as comparator groups (table 1).
Characteristics of patients with COVID-19
All patients with COVID- 19 were symptomatic and required 
hospitalisation, with the the most common symptom being 
dyspnoea (87%) and a smaller proportion presenting with chest 
pain (13%). Twenty- seven (52%) patients had severe disease 
with a Quick COVID- 19 severity score of greater than 4, 15 
(29%) requiring admission to the intensive care unit and 11 
(21%) undergoing non- invasive or invasive ventilation. Overall, 
29 (56%) patients had pre- existing cardiovascular disease or risk 
factors including hypertension, diabetes mellitus and hypercho-
lestrolaemia. Seventeen (33%) had an elevation in plasma high- 
sensitivity cardiac troponin I concentration above the normal 
upper reference limit (online supplemental table 1). Of those 
who underwent clinically indicated echocardiography during 
their hospital admission, 10 (19%) had an abnormal echocar-
diogram with six demonstrating right ventricular dilatation and 
three left ventricular dilatation (online supplemental table 2). 
Eight of the 10 patients with an abnormal baseline echocardio-
gram received either non- invasive or invasive ventilation. Of 









(n=10) P value* P value†
Age, median (IQR) (years) 55 (51–57) 53 (47–57) 35 (29–40) 0.58 <0.0001
Male 39 (75) 19 (73) 9 (90)
Body mass index, median (IQR) (kg/m2) 28 (18–42) 27 (22–41) 21 (22–27) 0.26 <0.001
Time of scan post symptoms onset median ±IQR (days) 90±(7–290) – –
Persistent symptoms, n (%) 20 (38) – –
Intensive care admission, n (%) 15 (29) – –
Endotracheal intubation, n (%) 5 (10) – –
Non- invasive ventilation, n (%) 6 (12) – –
Quick COVID- 19 severity index, n (%) – –
  Low 21 (40) –
  Low intermediate 13 (25) –
  High intermediate 14 (27) –
  High 4 (8) –
Medical history, n (%) –
  Hypertension 18 (35) 8 (31) –
  Ischaemic heart disease 8 (15) 5 (19) –
  Hypercholestrolaemia 16 (31) 8 (31) –
  Atrial fibrillation/flutter 2 (4) 1 (4) –
  Previous cerebrovascular event 1 (2) 0 –
  Diabetes mellitus 18 (35) 11 (38) –
  Non- cardiac 17 (33) 2 (8) –
Medications, n (%)
  Antiplatelet therapy 9 (17) 6 (23)
  Beta- blocker therapy 8 (15) 4 (15)
  ACE inhibitor or angiotensin receptor blocker therapy 14 (27) 9 (35)
  Diuretic therapy 2 (4) 0
  Statin therapy 16 (31) 10 (38)
  Antiglycaemic therapy 18 (35) 11 (42)
Smoking status, n (%)
  Non- smoker 43 (83) 14 54) 0
  Ex- smoker 8 (15) 10 (38) 0
  Current smoker 0 1 (4) 0
*Patients with COVID- 19 versus comorbidity- matched volunteers.
†Patients with COVID- 19 versus healthy volunteers.
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those who had CT pulmonary angiography as part of clinical 
care (n=19), two had evidence of pulmonary emboli.
CT coronary angiography
Twenty- three patients underwent CTCA and were scanned 90 
days (IQR: 7–290 days) following symptom onset. Sixty- five per 
cent of patients (15 of 23) had normal coronary arteries and 
35% (8 of 23) had evidence of coronary artery disease with one 
patient having obstructive disease (table 2). Within this subgroup, 
eight patients (35%) described persistent dyspnoea at the time of 
imaging, of whom seven demonstrated persistent parenchymal 
lung abnormalities at the time of imaging (figure 2).
Cardiac MRI
Patients with COVID-19 compared with healthy volunteers
In comparison with younger healthy volunteers, patients with 
COVID- 19 had reduced biventricular systolic function (table 3). 
Septal native myocardial T1 values (1225±46 (95% CI 1205 
to 1240) vs 1197±30 (95% CI 1178 to 1216) ms; p=0.04; 
figure 3), global native T1 values (table 3) and extracellular 
volume fraction (31±4 (95% CI 29.6 to 32.1) vs 24±3 (95% 
CI 33.4 to 25.4)%; p=0.0003; figure 3) were higher in patients 
with COVID- 19. None of the healthy volunteers had evidence 
of late gadolinium enhancement. Manganese- enhanced MRI 
demonstrated reduced uptake of myocardial manganese uptake 
in patients recovering from COVID- 19 (mean Ki 6.9±0.9 (95% 
CI 6.5 to 7.3) vs 7.9±1.2 (95% CI 7.4 to 8.5) mL/100 g/min; 
p=0.01, figure 3).
Patients with COVID-19 compared with comorbidity-matched 
volunteers
There were no major differences in left ventricular volumes and 
systolic function between patients and comorbidity- matched 
volunteers. However, patients recovering from COVID- 19 
did have reduced right ventricular systolic function (51.7±9.1 
(95% CI 53.9 to 60.1) vs 59.3±4.9 (95% CI 51.0 to 66.5)%; 
p=0.0005, table 3). When compared with comorbidity matched 
volunteers, septal native myocardial T1 values (1225±46 
(95% CI 1205 to 1240) vs 1227±51 (95% CI 1208 to 1246) 
ms; p=0.99, figure 3), global native T1 values (table 2) and 
extracellular volume fraction (31±4 (95% CI 29.6 to 32.1) vs 
29±5 (95% CI 27.0 to 31.2)%; p=0.35, figure 3) were similar. 
Myocardial manganese uptake (mean Ki 6.9±0.9 (95% CI 6.5 
to 7.3) vs 7.3±1.3 (95% CI 6.7 to 7.9) mL/100 g/min;p=0.45, 
figure 3) was also comparable. Late gadolinium enhancement was 
seen in 18 (35%) patients with COVID- 19, with nine demon-
strating a non- ischaemic pattern and nine with an ischaemic 
pattern (figure 4). None of the patients with a non- ischaemic 
pattern of late gadolinium enhancement had a history of prior 
cardiac disease and all had normal T2 values at the site of late 
enhancement (mean T2: 40.3±3.9 ms). Only one patient with 
an ischaemic pattern of enhancement had elevated T2 values in 
the corresponding region (45 ms). The prevalence of late gado-
linium enhancement was similar in the comorbidity- matched 
volunteers including right ventricular insertion point enhance-
ment (table 3, online supplemental table 3).
Influence of disease severity, myocardial injury and ongoing 
symptoms
In patients with severe COVID- 19 (27 of 52, 52%), left ventric-
ular function was preserved compared with matched volunteers. 
In contrast, right ventricular systolic function was reduced (EF 
52.2±10.2 (95% CI 48.1 to 56.2) vs 59.3±4.9 (95% CI 51.0 to 
66.5)%; p=0.0012). Native myocardial T1 values, extracellular 
volume fractions, myocardial manganese uptake and prevalence 
of late gadolinium enhancement were similar to comorbidity- 
matched volunteers (figure 5, online supplemental table 4).
Similar pattern was seen in patients with COVID- 19 and 
evidence of myocardial injury (online supplemental table 4). 
Native T1, extracellular volume fractions and myocardial 
manganese uptake were similar to comorbidity- matched volun-
teers (figure 5, online supplemental table 4). There was a higher 
prevalence of late gadolinium enhancement in this cohort 
compared with matched volunteers (9 of 17, 53% vs 9 of 26, 
35%), with the majority demonstrating an ischaemic pattern of 
injury (6 of 9, 66%).
Table 2 Coronary CT angiography findings
Patients with COVID- 19
(n=23)
Normal 15 (65)
Non- obstructive disease 7 (22)
  Mild (<50%) 4 (17)
  Moderate (50%–70%) 3 (13)
Obstructive disease 1 (4)
  One vessel 0
  Two vessels 1 (4)
  Three vessels 0
Other cardiac findings
  LV thrombus 1 (4)
  Anomalous coronary anatomy 1 (4)
Non- cardiac findings
  Parenchymal scarring/atelectasis 7 (30)
  Peripheral ground glass opacification 2 (9)
  Pulmonary mass or nodule 1 (4)
  Emphysema 3 (13)
  Hiatus hernia 1 (4)
  Liver pathology 2 (9)
  Pulmonary embolism 0
n (%).
LV, left ventricle.
Figure 2 Chest CT in severe COVID- 19. Typical COVID- 19 appearance 
with ground glass opacification (long arrow) and peripheral basal 
consolidation (short arrow) on during hospital admission (A) and 4 
months later (B) with residual atelectasis (short arrow) and subtle 
ground glass opacification (long arrow) in a patient with severe 
COVID- 19 with ongoing symptoms compared with a patient with 
COVID- 19 without symptoms (C).
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Twenty of 52 patients (38%) had ongoing symptoms at the time 
of scanning. While these patients had comparable left ventric-
ular systolic function to matched volunteers, they had reduced 
right ventricular systolic function (EF 49.0±6.5 (95% CI 45.9 to 
52.2) vs 59.3±4.9 (95% CI 51.0 to 66.5)%; p<0.0001; figure 5, 
online supplemental table 4). Native T1 values, extracellular 
volume fractions, myocardial manganese uptake and prevalence 
of late gadolinium enhancement were similar to comorbidity- 
matched volunteers (online supplemental table 4).
DISCUSSION
In this prospective multimodality two- centre observational 
study, we have shown that patients recovering from severe 
COVID- 19 do not have evidence of left ventricular dysfunc-
tion or a major excess in persistent myocardial injury compared 
with comorbidity- matched volunteers. These patients have a 
high prevalence of cardiovascular comorbidity that may account 
for much of the reported myocardial abnormalities on cardiac 
magnetic resonance. However, some patients recovering from 
COVID- 19 did have evidence of mild persistent right ventric-
ular dysfunction that likely reflects recovery from a severe life- 
threatening respiratory viral illness. It is possible that the cardiac 
consequences of COVID- 19 may relate to the severity of the 
pulmonary effects of COVID- 19 rather than direct cardiac 
effects of COVID- 19 infection.
Several studies have reported cardiac abnormalities on cardiac 
MRI in patients who have recovered from COVID- 19. These 
range from elevated native T1 and T2 values, to presence of 
cardiac dysfunction and late gadolinium enhancement.8 10–13 23–25 
Raman and colleagues25 described myocardial injury in a third 
of patients with moderate to severe COVID- 19, but they lacked 
a well- matched control population. Huang and colleagues10 
described abnormalities in 58% patients who had recently recov-
ered from COVID- 19 with ongoing cardiac symptoms although 
only a third of cases had evidence of late gadolinium enhance-
ment. Similarly, Puntmann and colleagues11 suggested that 70% 
of patients with COVID- 19 have ongoing cardiac damage, with 
32% of patients having late gadolinium enhancement and the 
majority having elevations in native T1 values or extracellular 
volume fraction. However, native T1 values vary between indi-
viduals and are affected by comorbidities, such as hypertension 
and diabetes mellitus.26 27 It is therefore not surprising that while 
we observed increased native T1 values in patients with COVID- 
19, these differences disappeared once comparisons were made 
with comorbidity- matched volunteers. Similar observations 
were made for extracellular volume fraction, T2 mapping and 
Table 3 MRI findings
Patients with
COVID- 19 (n=52)
Comorbidity- matched volunteers 
(n=26)
Healthy
volunteers (n=10) P value* P value†































































Main pulmonary artery, mean±SD (mm) 20.7±3.1 22.8±6.6 18.5±4.0 0.09 0.05
Late gadolinium enhancement pattern, n (%) 18 (35) 9 (35) 0
Ischaemic 9 (17) 5 (19) –
Non- ischaemic 9 (17) 4 (15) –





































Bold values are statistically significant (<0.05).
*Patients with COVID- 19 versus comorbidity- matched volunteers.
†Patients with COVID- 19 versus healthy volunteers.
‡n=23.
§n=20.
LV, left ventricular; LVEDVI, indexed left ventricular end- diastolic volume; LVESVI, indexed left ventricular end- systolic volume; RV, right ventricular; RVEDVI, indexed right ventricular end- diastolic 
volume; RVESVI, indexed right ventricular end- systolic volume.
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manganese assessments of myocyte function indicating that 
differences in these measures may relate to underlying comor-
bidities rather than persistent damage or injury from COVID- 19. 
Similar to previous studies,11 25 a third of our cohort demonstrate 
late gadolinium enhancement, which was comparable with our 
comorbidity- matched volunteer group, which included those 
with coronary artery disease. This begs the question whether 
individuals with cardiovascular risk factors, who are at higher 
risk of developing severe COVID- 19, demonstrate late gado-
linium enhancement as a result of their pre- existing conditions 
rather than COVID- 19 itself.
Figure 3 Cardiac MRI in patients with COVID- 19 compared with 
matched volunteers and healthy volunteers. Left ventricular (LV) ejection 
fraction (A), right ventricular (RV) ejection fraction (B), native T1 values 
(C) and extracellular volume (D) in healthy control volunteers (n=10, 
green), matched control volunteers (n=26, blue) and patients with 
COVID- 19 (n=52, red).
Figure 4 Cardiac magnetic resonance features in hospitalised COVID- 19 survivors. MRI findings in patients recovering from COVID- 19 infection 
compared with age, sex and comorbidity matched volunteers. *Statistically significant.
Figure 5 Cardiac MRI in subgroups of atients with COVID- 19 
compared with matched volunteers. Left ventricular (LV) ejection 
fraction (A), right ventricular (RV) ejection fraction (B), native T1 values 
(C) and extracellular volume (D) in matched control volunteers (n=26, 
green) and patients with COVID- 19 and severe COVID- 19 disease (n=27, 
red), myocardial injury (n=17, orange) or ongoing symptoms (n=20, 
blue).
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Kotecha and colleagues8 described similar native T1 and T2 
values in COVID- 19 survivors and comorbidity- matched volun-
teers. However, they demonstrated a higher rate of late gado-
linium enhancement (49%) in patients with COVID- 19 compared 
with our study and their matched control group. However, all 
their patients had elevated cardiac troponin concentrations and 
had been referred for cardiac MRI for clinical indications. Both 
factors will have introduced a case selection bias that will likely 
have increased their rate of late gadolinium enhancement. It has 
been suggested that non- ischaemic late gadolinium enhance-
ment could represent COVID- 19 related myocarditis, although 
without evidence on corresponding oedema imaging during the 
acute illness or other forms of validation, this cannot be estab-
lished. An inflammatory cardiomyopathy has previously been 
linked with several viruses including influenza28 but its associa-
tion with COVID- 19 remains unclear. Moreover, similar patterns 
of non- ischaemic late gadolinium enhancement are commonly 
observed in patients with hypertension and diabetes mellitus27 
in the absence of myocarditis. Regardless of the mechanism, the 
prognostic value of late gadolinium enhancement across multiple 
disease states probably warrants long- term follow- up.
Similar to previous studies,8 11 we observed that patients had 
evidence of increased right ventricular dysfunction, particularly 
in those with severe COVID- 19, myocardial injury and ongoing 
symptoms. Development of pulmonary fibrosis in severe 
acute respiratory syndrome coronovirus- 1 and adult respira-
tory distress syndrome have been reported in patients during 
recovery. Given SARS- CoV- 2 affinity for lung and heart tissues, 
it is possible severe lung injury in the setting of SARS- CoV- 2 
infection may lead to pulmonary fibrosis and elevated pulmo-
nary pressure. These are all risk factors for the development of 
right ventricular dysfunction.29 Furthermore, the persistence of 
symptoms in our patient cohort also related to persistent lung 
abnormalities observed on CT. However, due to the study size, 
this cannot be assumed, and further research should focus on 
patients with persistent symptoms.
We should consider the strengths and weaknesses of our study. 
We have undertaken a thorough assessment of cardiac structure 
and function with the use of multiple imaging modalities. While 
echocardiography is more practical and most widely used clini-
cally, we chose to use contrast- enhanced cardiac MRI to identify 
and to characterise any myocardial abnormalities since it is the 
most sensitive non- invasive measure to achieve this. Importantly, 
images were analysed by readers blinded to participant details 
and COVID- 19 status, a rigorous approach that was not always 
applied in previous studies. Manganese- enhanced MRI is a novel 
and sensitive measure of myocyte function,17 20 which allowed us 
to assess subtle changes alongside more traditional assessments 
of cardiac function. The use of CT coronary angiography also 
allowed assessment of both coronary artery disease and the pres-
ence of persistent lung damage. Despite this, we observed no 
left ventricular dysfunction when compared with appropriate 
comparator groups.
This study is limited by its modest sample size and the hetero-
geneity of patients surviving COVID- 19. However, we have 
focused on the patient cohort of most interest, patients recov-
ering following hospitalisation with severe COVID- 19. Other 
limitations of our study include the use of evolving therapeutic 
interventions and, perhaps more importantly, survival bias. As 
the pandemic evolved, new therapeutic interventions, such as 
dexamethasone, were introduced to reduce mortality, and this 
could also have influenced our findings. Over half of the patients 
who were eligible for the study died, and it is certainly possible 
that more extensive abnormalities could have been observed 
had earlier imaging been possible in these patients. As a conse-
quence, our findings are limited to the population of patients 
who recover from severe COVID- 19. It is difficult to ascertain 
whether the abnormalities seen in patients with COVID- 19 
were present prior to hospitalisation; however, it is reassuring 
that there was no excess in left ventricular abnormalities when 
compared with matched volunteers. Lastly, in an ideal world, a 
comparator group should include patients with non- COVID- 19 
viral or bacterial pneumonitis patients with a similar incidence 
of intensive care admissions, and this is an area for future studies 
to focus on.
In conclusion, concomitant comorbidities and risk factors play 
a major role in prior reports of left ventricular abnormalities 
associated with COVID- 19. In patients who recovered from 
severe COVID- 19, there was evidence of persistent right ventric-
ular dysfunction that presumably reflects the recent severe viral 
pneumonia and consequent pulmonary hypertension.
Key messages
What is already known on this subject??
 ► There is major interest in the cardiac consequences of 
COVID- 19, and it is essential to establish the true impact of 
COVID- 19 and how it will affect healthcare in the years to 
follow.
What might this study add??
 ► This study shows that the consequences of abnormalities 
seen on cardiac MRI in patients with COVID- 19 remain 
unclear. Many abnormalities may be attributable to 
comorbidity and concomitant cardiovascular risk factors 
rather than COVID- 19 per se. Right ventricular abnormalities 
do occur and likely reflect the consequences of a severe viral 
pneumonia.
How might this impact on clinical practice?
 ► Further research is needed to establish the true extent of 
cardiac abnormalities in patients who have suffered severe 
COVID- 19 and to determine whether this is likely to impact 
on their long- term clinical outcome.
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